|
This information has been developed and provided by an independent third-party source. Merck & Co., Inc. does not endorse and is not responsible for the accuracy of the content, or for practices or
standards of non-Merck sources.
Pronunciation
(SYE kli zeen)
U.S. Brand Names
Index Terms
Generic Available
No
Pharmacologic Category
Pharmacologic Category Synonyms
Use: Labeled Indications
Prevention and treatment of nausea, vomiting, and vertigo associated with motion sickness; control of postoperative nausea and vomiting
Pregnancy Risk Factor
B
Contraindications
Hypersensitivity to cyclizine or any component of the formulation
Adverse Reactions
>10%:
Central nervous system: Drowsiness
Gastrointestinal: Xerostomia
1% to 10%:
Central nervous system: Headache
Dermatologic: Dermatitis
Gastrointestinal: Nausea
Genitourinary: Urinary retention
Ocular: Diplopia
Renal: Polyuria
Drug Interactions
Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial. Risk C: Monitor therapy
Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy
Amphetamines: May diminish the sedative effect of Antihistamines. Risk C: Monitor therapy
Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics. Exceptions: Paliperidone. Risk C: Monitor therapy
Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Risk C: Monitor therapy
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy
Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract. Risk D: Consider therapy modification
Ethanol/Nutrition/Herb Interactions
Ethanol: Avoid ethanol (may increase CNS depression).
Mechanism of Action
Cyclizine is a piperazine derivative with properties of histamines. The precise mechanism of action in inhibiting the symptoms of motion sickness is not known. It may have effects directly on the labyrinthine apparatus and central actions on the labyrinthine apparatus and on the chemoreceptor trigger zone. Cyclizine exerts a central anticholinergic action.
Dosage
Oral:
Children 6-12 years: 25 mg up to 3 times/day
Adults: 50 mg taken 30 minutes before departure, may repeat in 4-6 hours if needed, up to 200 mg/day
Geriatric Considerations
Due to anticholinergic action, use lowest dose in divided doses to avoid side effects and their inconvenience; limit use if possible; may cause confusion or aggravate symptoms of confusion in those with dementia; constipation and difficulty voiding urine may occur
Dental Health: Effects on Dental Treatment
Key adverse event(s) related to dental treatment: Xerostomia (normal salivary flow resumes upon discontinuation).
Dental Health: Vasoconstrictor/Local Anesthetic Precautions
No information available to require special precautions
Mental Health: Effects on Mental Status
Drowsiness is common
Mental Health: Effects on Psychiatric Treatment
Concurrent use with psychotropics may exacerbate the dry mouth and sedation commonly seen with cyclizine
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, as hydrochloride:
Marezine®: 50 mg
Tablet, chewable, as hydrochloride:
Bonine® for Kids: 25 mg [berry blast flavor]
International Brand Names
Lexi-Comp.com
Last full review/revision January 2009
Content last modified January 2009
| 
